Skip to main content

Advertisement

SpringerLink
Log in

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Therapeutic options for patients with relapsed or refractory acute leukemia are still undefined and often unsatisfactory. We report the outcome of 79 patients with relapsed-refractory acute leukemia treated with fludarabine, cytarabine, and liposomal daunorubicin (FLAD regimen) followed by hematopoietic stem cell transplantation (HSCT), when clinically indicated, between May 2000 and January 2013. Forty-one patients had acute myeloid leukemia (AML), and 38 had acute lymphoblastic leukemia (ALL). Two patients with myeloid blast crises of CML and three with lymphoid blast crises were included in the AML and ALL subgroups, respectively. Median age was 48 years (range 13–77). FLAD was well tolerated with negligible, nonhematological toxicity. Six patients (7.5 %) died before response evaluation. Forty-seven patients achieved hematologic complete response (CR). Complete remission rate was 53 and 65 % among AML and ALL patients, respectively. No CR was recorded among 11 refractory AML patients. Twenty-four patients (30 %) underwent HSCT. Nine patients received stem cells from an HLA identical sibling, and 15 from an alternative donor (3 unrelated matched, 12 haploidentical sibling). Median overall survival in AML and ALL patients receiving FLAD therapy was 9 and 8 months, respectively. A 5-year projected OS for patients receiving the whole program (FLAD + HSCT) was 24 % for AML patients (median survival 43 months), 28 % for ALL patients treated in relapse (median survival 15 months), and 0 % for ALL patients treated for refractory disease. In this paper, we show that FLAD seems to be an effective bridge therapy to HSCT for a part of poor prognosis acute leukemia patients. However, prospective studies are needed to confirm our results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fielding AK, Richards SM, Chopra R et al (2007) Medical Research Council of the United Kingdom Adult ALL Working Party. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood 109:944–950

    Article  CAS  PubMed  Google Scholar 

  2. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S (2010) Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475–480

    Article  PubMed Central  PubMed  Google Scholar 

  3. Tavernier E, Boiron JM, Huguet F, GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group et al (2007) Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:1907–1914

    Article  CAS  PubMed  Google Scholar 

  4. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186–3191

    Article  PubMed Central  PubMed  Google Scholar 

  5. Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS, Eastern Cooperative Oncology Group LeukemiaCommittee (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148(2):217–225

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Jeha S, Gandhi V, Chan KW et al (2004) Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784–789

    Article  CAS  PubMed  Google Scholar 

  7. DeAngelo DJ, Yu D, Johnson JL et al (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136–5142

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Ottmann OG, Druker BJ, Sawyers CL et al (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965–1971

    Article  CAS  PubMed  Google Scholar 

  9. Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309–2315

    Article  CAS  PubMed  Google Scholar 

  10. Tischer J, Stemmler HJ, Engel N, Hubmann M, Fritsch S, Prevalsek D, Schulz C, Zoellner AK, Bücklein V, Hill W, Ledderose G, Hausmann A (2013) Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann Hematol 92(10):1379–1388

    Article  CAS  PubMed  Google Scholar 

  11. Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P (2014) Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol 89(4):399–403

  12. Tsunemine H, Akasaka H, Sakane EI, Ito K, Kodaka T, Takahashi T (2014) Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone. Int J Hematol 99(2):193–197

    Article  PubMed  Google Scholar 

  13. Pierri I, Miglino M, Gatto S, Venturino C, Quintino S, Beltrami G, Lanino E, Clavio M, Canepa L, Gobbi M (2000) Combination of liposomal daunorubicin (Daunoxome), fludarabine and cytarabine as salvage therapy in relapsed and refractory acute leukemia. Blood 96(suppl 2):215b

    Google Scholar 

  14. Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 83(11):696–703

    Article  CAS  PubMed  Google Scholar 

  15. Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R (2006) Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol 77(4):293–299

    Article  PubMed  Google Scholar 

  16. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92:7–14

    Article  CAS  PubMed  Google Scholar 

  17. Russo D, Piccaluga PP, Michieli M, Michelutti T, Visani G, Gugliotta L, Bonini A, Pierri I, Gobbi M, Tiribelli M, Fanin R, Piccolrovazzi S, Baccarani M (2002) Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Haematol 81:462–466

    Article  CAS  Google Scholar 

  18. Baccarani M, Russo D, Fanin R, Michieli M (2000) Liposomal daunorubicin (Daunoxome) in the treatment of acute lymphocytic leukemia (ALL). Blood 96(suppl 1):720a, abtr. 3110

    Google Scholar 

  19. Ermacora A, Michieli M, Pea F, Visani G, Bucalossi A, Russo D (2000) Liposome encapsulated daunorubicin (Daunoxome) for acute leukemia. Haematologica 85:324–325

    CAS  PubMed  Google Scholar 

  20. Piccaluga PP, Visani G, Martinelli G, Isidori A, Malagola M, Rondoni M, Baccarani M, Tura S (2010) Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia 16(9):1880–1881

    Article  Google Scholar 

  21. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Bacigalupo A, Varaldo R (2013) Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies aftermyeloablative conditioning. Biol Blood Marrow Transplant 19(1):117–122

    Article  CAS  PubMed  Google Scholar 

  22. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A (2008) Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 9(9):831–839. doi:10.1016/S1470-2045(08)70180-3

    Article  CAS  PubMed  Google Scholar 

  23. Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF, Grupo Español de Trasplante Hematopoyético y Terapia Celular (2012) Single-unit umbilical cord blood transplantation from unrelated donors in patients with haematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 47(10):1287–1293

    Article  CAS  PubMed  Google Scholar 

  24. Michieli M, Damiani D, Ermacora A, Masolini P, Michielutti A, Michelutti T, Russo D, Pea F, Baccarani M (1999) Liposomal-encapsulated daunorubicin for Pgp-related multidrug resistance. Br J Haematol 106:92–99

    Article  CAS  PubMed  Google Scholar 

  25. Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F (2009) Sequentialcontinuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute. myeloid leukemia patients. Ann Hematol 88(2):151–158

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Clinical Hematology and Division of Hematology and Hematopoietic Stem Cell Transplantation, IRCCS S Martino-IST, Viale Benedetto XV, N 6, 16132, Genova, Italy

    Enrico De Astis, Marino Clavio, Anna Maria Raiola, Anna Ghiso, Fabio Guolo, Paola Minetto, Federica Galaverna, Maurizio Miglino, Carmen Di Grazia, Filippo Ballerini, Carlo Marani, Giordana Pastori, Laura Mitscheunig, Fabio Cruciani, Davide Lovera, Riccardo Varaldo, Chiara Ghiggi, Roberto Massimo Lemoli, Andrea Bacigalupo & Marco Gobbi

Authors
  1. Enrico De Astis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marino Clavio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Maria Raiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Ghiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabio Guolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paola Minetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Federica Galaverna
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maurizio Miglino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carmen Di Grazia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Filippo Ballerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Carlo Marani
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Giordana Pastori
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Laura Mitscheunig
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Fabio Cruciani
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Davide Lovera
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Riccardo Varaldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Chiara Ghiggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Roberto Massimo Lemoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Andrea Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Marco Gobbi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marino Clavio.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Astis, E., Clavio, M., Raiola, A.M. et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol 93, 2011–2018 (2014). https://doi.org/10.1007/s00277-014-2143-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2143-8

Keywords

Search

Navigation